Legis Daily

PART Act

USA116th CongressS-3781| Senate 
| Updated: 5/20/2020
Gary C. Peters

Gary C. Peters

Democratic Senator

Michigan

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Pharmaceutical Accountability, Responsibility, and Transparency Act or the PART Act This bill expands requirements for manufacturers of certain drugs and medical devices to report information to the Food and Drug Administration (FDA) and contains related provisions. A manufacturer of a life-saving drug or medical device must notify the FDA of certain issues that may affect the drug or device's availability, such as an increase in demand that the manufacturer is likely unable to meet or an export restriction imposed by a foreign country where the drug or device is being manufactured. The manufacturer must notify the FDA within five days of becoming aware of the issue. The bill also expands the types of foreign manufacturers of drugs and medical devices that must register with the FDA. Additionally, the bill expands a requirement for registered manufacturers to submit periodic reports to the FDA by (1) increasing the frequency of such reports, and (2) requiring the reports to include additional information about the amounts of drugs and medical devices being manufactured.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 20, 2020
Introduced in Senate
May 20, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 20, 2020
    Introduced in Senate


  • May 20, 2020
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

Business recordsDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careGovernment information and archivesHealth technology, devices, suppliesManufacturingPrescription drugsPublic contracts and procurementStrategic materials and reservesTrade restrictions

PART Act

USA116th CongressS-3781| Senate 
| Updated: 5/20/2020
Pharmaceutical Accountability, Responsibility, and Transparency Act or the PART Act This bill expands requirements for manufacturers of certain drugs and medical devices to report information to the Food and Drug Administration (FDA) and contains related provisions. A manufacturer of a life-saving drug or medical device must notify the FDA of certain issues that may affect the drug or device's availability, such as an increase in demand that the manufacturer is likely unable to meet or an export restriction imposed by a foreign country where the drug or device is being manufactured. The manufacturer must notify the FDA within five days of becoming aware of the issue. The bill also expands the types of foreign manufacturers of drugs and medical devices that must register with the FDA. Additionally, the bill expands a requirement for registered manufacturers to submit periodic reports to the FDA by (1) increasing the frequency of such reports, and (2) requiring the reports to include additional information about the amounts of drugs and medical devices being manufactured.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 20, 2020
Introduced in Senate
May 20, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 20, 2020
    Introduced in Senate


  • May 20, 2020
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Gary C. Peters

Gary C. Peters

Democratic Senator

Michigan

Health, Education, Labor, and Pensions Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careGovernment information and archivesHealth technology, devices, suppliesManufacturingPrescription drugsPublic contracts and procurementStrategic materials and reservesTrade restrictions